Novavax has reported a net loss of $7.22m, or $0.05 per share, for the third quarter ended 30 September 2012 compared to a net loss of $3.21m, or $0.03 per share, for the third quarter ended 30 September 2011. Revenue for third quarter of ...
Tags: Novavax, Wider Q3 Net Loss, net loss, clinical trials